A day ahead of its PDUFA date, Mepsevii (vestronidase alfa-vjbk, previously UX-003) won FDA approval to treat children and adults with the ultra rare inherited metabolic condition mucopolysaccharidosis type VII (MPS VII), also known as Sly syndrome. The nod gave developer Ultragenyx Pharmaceutical Inc. its first commercial product and represented a first approval in the indication.